Medtronic to Acquire Twelve, Inc., Developer of Transcatheter Mitral Valve Replacement Device
August 25, 2015Twelve is the twelfth company spun out from the premier medical device incubator The Foundry. Medtronic has agreed to pay up to $458 million for Twelve including $408 million at closing and $50 million on achievement of CE Marking.
More »
Celator(R) Pharmaceuticals Appoints Michael R. Dougherty as Executive Chairman of Board of Directors
August 24, 2015With over 30 years of experience in the biopharmaceuticals industry, Daugherty became a director of Celator in 2013 and has served as Chairman since September 2014. Celator is transforming the science of combination therapy for cancer.
More »
Syndax Raises $80 Million in Series C Financing
August 24, 2015Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Proceeds will fund further development of entinostat.
More »